ISGD Welcomes CMSO Barbara S. Gillespie

Published on January 1, 2026
ISGD Welcomes CMSO Barbara S. Gillespie

The International Society of Glomerular Disease is pleased to welcome Barbara Gillespie, MD, MMS, FASN, into the advisory role of Chief Medical and Strategy Officer. In this capacity she will strengthen collaboration across the glomerular disease ecosystem to advance scientific and clinical development, novel therapies, and key ISGD initiatives, including Centers of Excellence, endpoint initiatives, and clinical trial programs.

Continue reading on website
Other news

The Cutting Edge: A Clinicopathology Minireview of Immunoglobulin A Nephropathy

December 31, 2025
AbstractRecent years have seen an explosion of interest in the pathogenesis and therapy of immunoglobulin A nephropathy (IgAN). Large cohort studies have facilitated improvements in disease classification and prognosis, including the establishment and validation of a standard pathological classification, the Oxford classification. Landmark treatment studies published in the past several years have

Examining Referral Pathways for Patients with Hematuria: A Real-World Retrospective Analysis

January 22, 2026
AbstractIntroduction: Follow-up for hematuria, often found incidentally on urinalysis, is critical as it may be an early sign of glomerular disease or malignancy. We evaluated nephrology and urology referral patterns for outpatients with hematuria, and factors associated with nephrology and urology referrals. Methods: This retrospective, observational cohort study leveraged electronic health recor